CERo Therapeutics Holdings (CERo Therapeutics Holdings) Accounts Receivable : $0.00 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. CERo Therapeutics Holdings's accounts receivables for the quarter that ended in Dec. 2022 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. CERo Therapeutics Holdings's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $-3.83.

CERo Therapeutics Holdings Accounts Receivable Historical Data

The historical data trend for CERo Therapeutics Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Accounts Receivable Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Accounts Receivable

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Accounts Receivable	-	-

CERo Therapeutics Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

CERo Therapeutics Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

CERo Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), CERo Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:

CERo Therapeutics Holdings's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(6.82	+	0.75 * 0	+	0.5 * 0	-	46.22
-	0	-	0)	/	10.293
=	-3.83

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

CERo Therapeutics Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024